Diabetic Macular Edema

At Oxurion we are dedicated to developing innovative treatments to improve and better preserve vision for patients with diabetic macular edema (DME).


Unmet Need

DME, the leading cause of vision loss in working-age adults, is a large and growing health concern, with an urgent demand to address unmet patient needs.


Unique Research

Anti-VEGF treatment is the mainstay of therapy today but not all patients have elevated VEGF levels. We focus on plasma kallikrein (PKal), a key driver in the pathogenesis of DME.



THR-149, our potent PKal inhibitor currently in a Phase 2 clinical trial, is being developed as a potential new standard of care for the up to 50% of patients with DME who respond suboptimally to anti-VEGF treatment.

Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Advancing Science. Enhancing Vision.

Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, our novel therapeutic for the treatment of DME.

We are committed to helping improve and preserve vision for patients with retinal disorders.

- Patrik De Haes, MD, Non-Executive Chairman of Oxurion



Oxurion employees are united by a shared goal: to make Oxurion a global leader in developing innovative treatments for retinal disorders including diabetic macular edema (DME). Want to join us?

Visit our careers site


Oxurion relies on a network of experienced partners to bring the best possible eye care to patients across the globe. We are always open to new opportunities for partnership and collaboration for improving eye care.

Want to become a partner? Contact us!

Stay in touch

Be sure to check in regularly for the latest news about our our company, research & development activities and updates for investors or just subscribe to our mailing list to receive regular updates.

Read our latest news or Subscribe